
Kyverna Therapeutics aims for first approved cell therapy for autoimmune disease by Q4 2026.
Kyverna Therapeutics is progressing toward filing its Biologics License Application (BLA) by Q4 2026 for a cell therapy targeting Stiff Person syndrome, a rare autoimmune disease with no current approved treatments. If successful, this would mark the...





